IL1A and rheumatoid arthritis: Further studies are required, but the positive outcomes reported by Kyriazopoulou et al. provide clear grounds for optimism, mainly when considered with the promising observational data of Cavalli et al. There may also be a pharmacogenomic effect associated with the drug because it was previously reported that rheumatoid arthritis (RA) patients with IL‐1α + 4,845(G > T) polymorphism may respond better to anakinra (Camp et al., 2005).